Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- National Aeronautics and Space Administration
- Branch
- Not reported
- Recipient company
- Agility Innovations, LLC
- Proposal award date
- 2019-08-14
- Contract end date
- 2021-08-13
- UEI
- GF9PWMNBHEJ3
- Solicitation number
- SBIR_18_P2
- Topic code
- H3
Research abstract
Silver and its compounds are of significant appeal as biocides for long-duration space missions, as they are capable of destroying or inhibiting the growth of a wide spectrum of microorganisms including bacteria, viruses, algae, molds and yeast, while exhibiting low toxicity to humans. The general pharmacological properties of silver are based upon the affinity of silver ion for biologically important moieties such as sulfhydryl, amino, imidazole, carboxyl and phosphate groups, and these multiple mechanisms are primarily responsible for its antimicrobial activity. Silver can impact a cell through multiple biochemical pathways, making it difficult for a cell to develop resistance to it, and it can be precisely and efficiently delivered using controlled-release technology.An engineering approach is detailed that optimizes the epidemiological features of silver compounds in conjunction with the chemical and mechanical design features desirable for long-duration space missions. Phase I builds upon three distinct engineering approaches to produce flow-through silver biocide delivery devices based on controlled-release designs that have multiple decades of success in process industrial applications. Phase II will consist of design optimization and extensive parametric testing to support on-site NASA tests and long-duration flight requirements. Phase II will also investigate a regenerate approach to maintaining device activity over multi-year operational lifetimes, and advanced QA/QC protocols that will ensure effectiveness in very long term and remote applications on Mars and Lunar bases. The long-term results and benefits to the manned space program are high antimicrobial effectiveness, low toxicity, simple operation and integration into advanced life support systems, maximum operational life, and superior mass/volume efficiency compared to any other possible approach.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
22 SBIR/STTR records share this UEI (1993–2019). Reported award amounts total $5,774,425. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Aeronautics and Space Administration, Department of Health and Human Services, Department of Energy, Department of Defense
Agency intelligence
National Aeronautics and Space Administration
Back to SBIR/STTR Research Awards